Julien Hadoux
Expertise in
16
conditions

Julien Hadoux

Gustave Roussy
Villejuif, FR 
Expertise in
16
conditions
Gustave Roussy
Villejuif, FR 

Overview

Julien Hadoux practices practicing medicine in Villejuif, France.

Mr. Hadoux is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroidectomy, and Parathyroidectomy.

He is actively involved in clinical research, co-authoring 128 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Surufatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

128 Total Publications

Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor.
Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor.
Journal: Journal of visceral surgery
Published: August 11, 2026

Frequently Asked Questions about Julien Hadoux

Is Julien Hadoux a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Julien Hadoux is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Julien Hadoux participate in research or clinical trials?

Yes. Julien Hadoux has published 128 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Julien Hadoux's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hadoux's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile